Genprex (GNPX) 10-K 1 Apr 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 25, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001595248
Entity Registrant Name	Genprex, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-38244
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772347
Entity Address, Address Line One	3300 Bee Cave Road #650-227
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78746
City Area Code	877
Local Phone Number	774-4679
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GNPX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Financial Statement Error Correction [Flag]	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 48,500,000
Entity Common Stock, Shares Outstanding		1,910,441
Auditor Name	WithumSmith+Brown, PC
Auditor Location	East Brunswick, New Jersey
Auditor Firm ID	100

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,737,629	$ 20,954,069
Accounts receivable	0	34,852
Prepaid expenses and other	794,138	484,224
Total current assets	7,531,767	21,473,145
Property and equipment, net	7,859	23,032
Other assets:
Security deposits	10,000	21,818
Research and development supplies	2,347,488	2,864,937
Intellectual property, net	773,478	702,095
Total other assets	3,130,966	3,588,850
Total assets	10,670,592	25,085,027
Current liabilities:
Accounts payables	1,397,610	442,925
Other current liabilities	1,856,598	2,367,362
Total current liabilities	3,254,208	2,810,287
Stockholders' equity:
Common stock $0.001 par value: 200,000,000 shares authorized; 1,485,902 and 1,202,677 shares issued and outstanding, respectively	1,486	1,203
Additional paid-in capital	141,103,178	125,101,356
Accumulated deficit	(133,688,280)	(102,827,819)
Total stockholders' equity	7,416,384	22,274,740
Total liabilities and stockholders' equity	$ 10,670,592	$ 25,085,027

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	1,485,902	1,202,677
Common stock, shares outstanding (in shares)	1,485,902	1,202,677

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 0	$ 0
Cost and expenses:
Depreciation	15,004	25,575
Research and development	17,616,605	11,510,074
General and administrative	13,443,961	12,295,070
Total costs and expenses	31,075,570	23,830,719
Operating loss	(31,075,570)	(23,830,719)
Interest income	215,109	90,098
Net loss	$ (30,860,461)	$ (23,740,621)
Net loss per share — basic and diluted (in dollars per share)	$ (22.56)	$ (19.8)
Weighted average number of common shares — basic and diluted (in shares)	1,367,747	1,198,837

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	1,196,893
Balance at Dec. 31, 2021	$ 1,197	$ 120,362,992	$ (79,087,198)	$ 41,276,991
Issuance of common stock for cash (in shares)	3,023
Issuance of common stock for cash	$ 3	6,423	0	6,426
Issuance of common stock for services (in shares)	2,761
Issuance of common stock for services	$ 3	163,229	0	163,232
Share-based compensation	0	4,568,712	0	4,568,712
Net loss	$ 0	0	(23,740,621)	(23,740,621)
Balance (in shares) at Dec. 31, 2022	1,202,677
Balance at Dec. 31, 2022	$ 1,203	125,101,356	(102,827,819)	22,274,740
Issuance of common stock for services (in shares)	500
Issuance of common stock for services	$ 1	19,009	0	19,010
Share-based compensation	0	5,389,718	0	5,389,718
Net loss	$ 0	0	(30,860,461)	(30,860,461)
Issuance of common stock and warrants for cash net of issuance costs (in shares)	282,725
Issuance of common stock and warrants for cash net of issuance costs	$ 282	10,593,095	0	10,593,377
Balance (in shares) at Dec. 31, 2023	1,485,902
Balance at Dec. 31, 2023	$ 1,486	$ 141,103,178	$ (133,688,280)	$ 7,416,384

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (30,860,461)	$ (23,740,621)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	15,004	25,575
Share-based compensation	5,408,728	4,731,944
Changes in operating assets and liabilities:
Accounts receivable	34,852	(34,852)
Prepaid expenses and other	(309,914)	27,125
Research and development supplies	517,449	157,465
Deposits	11,818	(13,127)
Accounts payable	954,686	(530,269)
Other current liabilities	(510,765)	1,755,262
Net cash used in operating activities	(24,738,603)	(17,621,498)
Cash flows from investing activities:
Reductions to property and equipment	169	0
Additions to intellectual property	(71,383)	(59,735)
Net cash used in investing activities	(71,214)	(59,735)
Cash flows from financing activities:
Net proceeds from issuances of common stock	10,593,377	6,426
Net cash provided by financing activities	10,593,377	6,426
Net decrease in cash	(14,216,440)	(17,674,807)
Cash and cash equivalents, beginning of year	20,954,069	38,628,876
Cash and cash equivalents, end of year	$ 6,737,629	$ 20,954,069

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. Rule 10b5 1 10b5 1 During the fiscal quarter ended December 31, 2023, none 16a 1 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 Genprex, Inc. (“Genprex” or the “Company”), incorporated in Delaware in April 2008, 1 may 2 Oncology Platform Genprex’s lead oncology drug candidate, REQORSA® Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX- 001, Acclaim – 1: 2a 1/2 1 1 May 2023 1 1 1 1 2a no 1 2 “RP2D” 0.12 1 2a first January 2024. 2a 66 19 19 2a 2024, 2025. 1 Acclaim – 2: 1 1/2 2 2 0.06 first 2 2 0.09 0.12 March 2023, 2 second 2024. 2a RP2D. 2 The expansion portion of both the Acclaim- 1 2 2 RP2D 2 Acclaim – 3: 1 1/2 3 3 not January 2024, 1 3 1 second 2024 2 3 second 2024. June 2023, 3 not August 2023, The TUSC2 one 3 August 2022, three TUSC2 Diabetes Gene Therapy In diabetes, the Company has exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) multiple technologies relating to the development of a gene therapy product for each of Type 1 2 1 2 Pdx1 002 1 2 002 1 may 002 2 003 not December 2023, first 2024 October 2023, one August 2022 002 2 July 2023. Pdx1 1 2 7 10 February 2023, 1 002 16th 2023 April 2023, 1 2023 1 Capital Requirements, Liquidity and Going Concern Considerations The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, the Company has sustained substantial losses from operations since inception and has no The Company recognizes that it must obtain additional capital resources to successfully commercialize its product candidates. To date, Genprex has received funding in the form of equity and debt, and the Company plans to seek additional funding in the future. However, no not may not Genprex believes that its current cash and cash equivalents will be sufficient to fund expenditure requirements for its necessary operations and expected clinical trial activities into the third 2024. may no As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern. These financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Genprex’s financial statements have been prepared in accordance with US GAAP. Accordingly, they do not not not Reverse Stock Split On February 2, 2024, 1 not 4 Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no December 31, 2022 Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Genprex considers all highly liquid short-term investments with an initial maturity of three $250,000 December 31, 2023 2022 Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 632,323 unexercised options granted by the Company’s board of directors and warrants to purchase shares of common stock, and (ii) 51,862 unvested restricted stock units to purchase shares of common stock granted by the Company’s board of directors as of December 31, 2023 Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, money-market savings account, accounts receivable, and accounts payables approximate fair value because of the immediate or short-term maturity of these financial instruments. Property and Equipment Furniture and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Materials Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company's preclinical and Phase 1/2 Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have no Research and development supplies purchased and capitalized for future use were $2,347,488 and $2,864,937 at December 31, 2023 2022 Intellectual Property Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex that it believes contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining intellectual property protection, such as patent applications and filing fees associated with and patent protection, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. Accounting for Stock-Based Compensation Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognize the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Long-Lived Assets Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023 2022 no Recent Accounting Developments Accounting pronouncements issued but not December 31, 2023 not

Note 3 - Intellectual Property

Note 3 - Intellectual Property	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 3 As of December 31, 2023, University of Pittsburgh On February 11, 2020, 1 2 first August 17, 2022, November 3, 2022, 1 On November 22, 2022, 1 On December 29, 2022, Pdx1 2 On July 14, 2023, 1 2 Pdx1 The University of Texas MD Anderson Cancer Center On May 4, 2020, 7

Note 4 - Equity

Note 4 - Equity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 4 Reverse Stock Split On February 2, 2024, 1 not Registered Direct Offerings On March 1, 2023, 5 may On July 21, 2023, July 18, 2028. may See “Note 9 March 2024 March 2024 At-The Market Offering On November 18, 2022, may “2022 3 No. 333 239134 December 31, 2023 2022 December 12, 2023, 2022 December 13, 2023. On December 13, 2023, “2023 may may 3 No. 333 271386 April 21, 2023, June 9, 2023. three December 31, 2023, not 2023 See “Note 9 2023 2023 December 31, 2023 881,946 Stock Issuances During the year ended December 31, 2023 During the year ended December 31, 2022 Preferred Stock Genprex is authorized to issue 10,000,000 shares of preferred stock at a par value of $0.001 per share, none December 31, 2023 Common Stock Genprex is authorized to issue 200,000,000 shares of common stock at a par value of $0.001 per share, all of which is voting common stock. There were 1,485,902 shares of common stock outstanding at December 31, 2023 Common Stock Purchase Warrants Common stock purchase warrant activity for the years ended December 31, 2023 2022 2023 2022 Number of Weighted Average Number of Weighted Average Warrants Exercise Price Warrants Exercise Price Outstanding at January 1, 53,695 $ 172.81 55,121 $ 175.65 Warrants issued 296,273 38.75 2,575 61.55 Warrants exercised — — 342 20.00 Warrants cancelled or expired 3,528 209.77 3,659 151.66 Outstanding at December 31, 346,440 $ 57.79 53,695 $ 172.81 Exercisable at December 31, 340,585 $ 57.36 47,548 $ 183.42 During the year ended December 31, 2023 March 1, 2023, July 21, 2023, July 21, 2023, December 31, 2023 March 2018, December 31, 2023 During the year ended December 31, 2022 November 2019 December 31, 2022 As of December 31, 2023 12 five December 31, 2023 December 31, 2022 December 31, 2023 Twelve Months Ended December 31, 2023 Expected term (in years): 2.5 - 3.0 Risk-free rate: 5.33% - 5.52% Volatility: 83.42% Dividend yield: 0% 2018 Genprex’s board of directors and stockholders have approved and adopted the Company’s 2018 “2018 April 3, 2018. 2018 422 1986, may may The number of shares of common stock reserved for issuance under the 2018 January 1 January 1, 2019 December 31 2018 January 1, 2023 2022, 2018 December 31, 2023 2018 December 31, 2023 2018 2018 Genprex’s board of directors and stockholders approved and adopted the Company’s 2018 April 3, 2018. not may January 1 January 1, 2019, December 31 not January 1, 2023. Stock Options As of December 31, 2023 2018 2021 2023. ten Twelve Months Ended December 31, 2023 Twelve Months Ended December 31, 2022 Expected term (in years): 6.0 10 Risk-free rate: 4.60% – 5.37% 0.07% – 4.77% Volatility: 83.14% - 83.42% 75.98% - 88.38% Dividend yield: 0% 0% During the year ended December 31, 2023 During the year ended December 31, 2022 The weighted average remaining contractual term for the outstanding options at December 31, 2023 2022 Stock option activity for the years ended December 31, 2023 2022 2023 2022 Number of Weighted Average Number of Weighted Average Options Exercise Price Options Exercise Price Outstanding at January 1, 284,377 $ 123.19 214,370 $ 134.14 Options granted 8,251 30.14 74,600 86.45 Options exercised 500 11.92 2,925 0.60 Options expired or cancelled 6,245 104.42 1,668 101.88 Outstanding at December 31, 285,883 $ 121.11 284,377 $ 123.19 Exercisable at December 31, 237,859 $ 124.73 167,957 $ 129.19 Restricted Stock Units A summary of the RSU activity under the 2018 December 31, 2023 no December 31, 2022. 2023 Number of Weighted Average Units Grant Date Fair Value Outstanding at January 1, — $ — Restricted stock units granted 57,119 60.08 Restricted stock units forfeited or cancelled 5,257 66.00 Outstanding at December 31, 51,862 $ 59.48 Share-Based Compensation In the year ended December 31, 2023 December 31, 2023 not three December 31, 2023 As of December 31, 2023 one not may In the year ended December 31, 2022

Note 5 - 401(k) Savings Transac

Note 5 - 401(k) Savings Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Defined Contribution Plan [Text Block]	Note 5 401 Transactions In 2022, 401 “401 401 401 401 December 31, 2023 2022

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6 Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, Genprex’s President, Chief Executive Officer and Chairman of the Board and IRI’s sole officer. IRI is owned by trusts of which Mr. Varner’s descendants are the sole beneficiaries. In April 2009, August 2012, 2011 7

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7 Commitments MD Anderson In July 2018, two May 2022. August 2022, three December 31, 2023 In 2011, 1994 On March 3, 2021, May 4, 2020, six one TUSC2 TUSC2 five six one five December 31, 2023 National Institutes of Health Genprex has a royalty obligation to the National Institutes of Health (“NIH”) to be paid upon the Company’s receipt of FDA approval using NIH technology. The $240,000 contingent obligation which increases annually by $20,000 and is $360,000 and $340,000 for the years ended December 31, 2023 2022 University of Pittsburgh Pursuant to an exclusive license agreement dated February 11, 2020 August 17, 2022, November 3, 2022, first three first first 1 20 first December 31, 2023 Pursuant to an exclusive license agreement dated November 22, 2022 first three first first 1 20 first December 31, 2023 Pursuant to an exclusive license agreement dated December 29, 2022 first three first first 2 20 first December 31, 2023 Pursuant to an exclusive license agreement dated July 14, 2023, first second third fourth fourth first first 1 2 20 first December 31, 2023 Contract Development and Manufacturing Organization Genprex entered into a three July 2022, January 2023 March 2023, December 31, 2023 Contingencies From time to time, the Company may not

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8 Components of income tax benefit for the year ended December 31, 2023 2022 December 31, 2023 December 31, 2022 Current Tax Expense (Benefit): Federal — — State — — Total — — Deferred Tax Expense (Benefit): Federal — — State — — Total — — Total Provision for Income Taxes — — Temporary differences between financial statement carrying amount and tax basis of assets and liabilities that give rise to significant portions of the deferred tax assets and liabilities at December 31, 2023 2022 December 31, 2023 December 31, 2022 Deferred tax assets: Allowance for Doubtful Accounts — — Interest Expense — — Intangible Assets - R&D Expenses 4,710,079 1,986,102 Accrued Expenses 684,699 561,496 Tax Credits 1,434,851 728,701 Stock Compensation Expense 306,906 94,237 Net Operating Losses 16,915,002 14,464,170 Total Deferred Income Tax Assets 24,051,538 17,834,706 Deferred Income Tax Liabilities: Fixed Assets (1,650 ) (4,354 ) Intangible Assets — — Prepaid Expenses (629,136 ) (710,643 ) Lease - Right of Use — — Unrealized Gain/Loss — — Total Deferred Income Tax Liabilities (630,786 ) (714,997 ) Less Valuation Allowance (23,420,752 ) (17,119,710 ) Net Deferred Income Tax Asset — — At December 31, 2023 2022 In assessing the ability to realize the deferred tax assets, management considers whether it is more likely than not not December 31, 2023 2022 The Company has federal research and development (“R&D”) credit carryforwards of $1.4 million which will begin to expire in 2037. Effective January 1, 2009 740 10, No. 48, “FIN48” two first not second not 50

Note 9 - Subsequent Events

Note 9 - Subsequent Events	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 9 Reserves of 2018 2018 On January 1, 2024, 2018 March 14, 2024, no 2024 no Share Issuances On January 2, 2024, January 3, 2024, March 14, 2024, 2023 From January 1, 2024 10 2023 Reverse Stock Split At Genprex’s special meeting of stockholders held on December 14, 2023, not 1 10 not 1 50, January 19, 2024, 1 February 2, 2024. not 10 Departure of a Named Executive Officer Effective as of February 4, 2024, March 2024 On March 21, 2024, “March 2024 “March 2024 March 2024 March 2024 March 2024 March 2024 March 2024 may March 2024 March 2023 July 2023, March 1, 2028 July 21, 2028 five

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Reverse Stock Split, Policy [Policy Text Block]	Reverse Stock Split On February 2, 2024, 1 not 4
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no December 31, 2022
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Genprex considers all highly liquid short-term investments with an initial maturity of three $250,000 December 31, 2023 2022
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 632,323 unexercised options granted by the Company’s board of directors and warrants to purchase shares of common stock, and (ii) 51,862 unvested restricted stock units to purchase shares of common stock granted by the Company’s board of directors as of December 31, 2023
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, money-market savings account, accounts receivable, and accounts payables approximate fair value because of the immediate or short-term maturity of these financial instruments.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Furniture and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five
Research and Development Expense, Policy [Policy Text Block]	Research and Development Materials Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company's preclinical and Phase 1/2 Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have no Research and development supplies purchased and capitalized for future use were $2,347,488 and $2,864,937 at December 31, 2023 2022
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intellectual Property Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex that it believes contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining intellectual property protection, such as patent applications and filing fees associated with and patent protection, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognize the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023 2022 no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments Accounting pronouncements issued but not December 31, 2023 not

Note 4 - Equity (Tables)

Note 4 - Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	2023 2022 Number of Weighted Average Number of Weighted Average Warrants Exercise Price Warrants Exercise Price Outstanding at January 1, 53,695 $ 172.81 55,121 $ 175.65 Warrants issued 296,273 38.75 2,575 61.55 Warrants exercised — — 342 20.00 Warrants cancelled or expired 3,528 209.77 3,659 151.66 Outstanding at December 31, 346,440 $ 57.79 53,695 $ 172.81 Exercisable at December 31, 340,585 $ 57.36 47,548 $ 183.42
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Twelve Months Ended December 31, 2023 Expected term (in years): 2.5 - 3.0 Risk-free rate: 5.33% - 5.52% Volatility: 83.42% Dividend yield: 0% Twelve Months Ended December 31, 2023 Twelve Months Ended December 31, 2022 Expected term (in years): 6.0 10 Risk-free rate: 4.60% – 5.37% 0.07% – 4.77% Volatility: 83.14% - 83.42% 75.98% - 88.38% Dividend yield: 0% 0%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	2023 2022 Number of Weighted Average Number of Weighted Average Options Exercise Price Options Exercise Price Outstanding at January 1, 284,377 $ 123.19 214,370 $ 134.14 Options granted 8,251 30.14 74,600 86.45 Options exercised 500 11.92 2,925 0.60 Options expired or cancelled 6,245 104.42 1,668 101.88 Outstanding at December 31, 285,883 $ 121.11 284,377 $ 123.19 Exercisable at December 31, 237,859 $ 124.73 167,957 $ 129.19
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	2023 Number of Weighted Average Units Grant Date Fair Value Outstanding at January 1, — $ — Restricted stock units granted 57,119 60.08 Restricted stock units forfeited or cancelled 5,257 66.00 Outstanding at December 31, 51,862 $ 59.48

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	December 31, 2023 December 31, 2022 Current Tax Expense (Benefit): Federal — — State — — Total — — Deferred Tax Expense (Benefit): Federal — — State — — Total — — Total Provision for Income Taxes — —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2023 December 31, 2022 Deferred tax assets: Allowance for Doubtful Accounts — — Interest Expense — — Intangible Assets - R&D Expenses 4,710,079 1,986,102 Accrued Expenses 684,699 561,496 Tax Credits 1,434,851 728,701 Stock Compensation Expense 306,906 94,237 Net Operating Losses 16,915,002 14,464,170 Total Deferred Income Tax Assets 24,051,538 17,834,706 Deferred Income Tax Liabilities: Fixed Assets (1,650 ) (4,354 ) Intangible Assets — — Prepaid Expenses (629,136 ) (710,643 ) Lease - Right of Use — — Unrealized Gain/Loss — — Total Deferred Income Tax Liabilities (630,786 ) (714,997 ) Less Valuation Allowance (23,420,752 ) (17,119,710 ) Net Deferred Income Tax Asset — —

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual)			12 Months Ended
	Feb. 02, 2024	Jan. 19, 2024	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)
Cash, Uninsured Amount			$ 6,490,117	$ 20,679,538
Research and Development Assets, Current			2,347,488	2,864,937
Impairment, Long-Lived Asset, Held-for-Use			$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			5 years
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares			632,323
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares			51,862
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	40	40

Note 3 - Intellectual Property

Note 3 - Intellectual Property (Details Textual)	12 Months Ended
	Dec. 31, 2023
Number of Granted Patents	21
Number of Pending Patent Applications	23

Note 4 - Equity (Details Textua

Note 4 - Equity (Details Textual)													1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 21, 2024 USD ($) $ / shares shares	Feb. 02, 2024	Jan. 19, 2024	Jan. 02, 2024 shares	Jan. 01, 2024 shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 13, 2023	Jul. 21, 2023 USD ($) $ / shares shares	Mar. 01, 2023 USD ($) $ / shares shares	Jan. 01, 2023 shares	Nov. 18, 2022 USD ($)	Jan. 01, 2022 shares	Mar. 31, 2024 USD ($)	Mar. 28, 2024 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares shares	Apr. 03, 2018 shares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						346,440									346,440
Warrants and Rights Outstanding, Term (Year)						5 years									5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 57.79									$ 57.79	$ 172.81	$ 175.65
Proceeds from Issuance of Common Stock | $															$ 10,593,377	$ 6,426
Stock Issued During Period, Value, Issued for Services | $															$ 19,010	$ 163,232
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)															500	2,925
Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares)																342
Preferred Stock, Shares Authorized (in shares)						10,000,000									10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001									$ 0.001
Preferred Stock, Shares Outstanding (in shares)						0									0
Common Stock, Shares Authorized (in shares)						200,000,000									200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001									$ 0.001	$ 0.001
Common Stock, Shares, Outstanding (in shares)						1,485,902									1,485,902	1,202,677
Class of Warrant or Right, Issued in Period (in shares)															296,273	2,575
Class of Warrant or Right, Cancelled During Period (in shares)															3,528	3,659
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						285,883									285,883	284,377	214,370
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)															10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares						$ 121.11									$ 121.11	$ 123.19	$ 134.14
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															8,251	74,600
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares															$ 30.14	$ 86.45
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period (in shares)															6,245	1,668
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares															$ 104.42	$ 101.88
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)															6 years 1 month 17 days	7 years 29 days
Class of Warrant or Right, Outstanding (in shares)						346,440									346,440	53,695	55,121
Options and Warrants [Member]
Share-Based Payment Arrangement, Expense | $															$ 5,400,000
Options and Warrants [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense | $															4,400,000
Options and Warrants [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense | $															1,000,000
Time-Based Stock Option Awards, RSUs, and Warrants [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $						$ 4,700,000									$ 4,700,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)															3 years
Time-Based Stock Option Awards, RSUs, and Warrants [Member] | Related to General and Administrative Expense [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $						3,800,000									$ 3,800,000
Time-Based Stock Option Awards, RSUs, and Warrants [Member] | Related to Research and Development Expense [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $						$ 900,000									$ 900,000
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						0									0
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense | $																$ 4,700,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $																$ 4,600,000
The 2018 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year																		5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)						74,294				60,132		59,843
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)						11,686									11,686
The 2018 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year																		2%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)																		5,202
Excluding the 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						25,417									25,417
Scientific Advisory Board Chairman [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)															500	500
Stock Issued During Period, Value, Issued for Services | $															$ 19,200	$ 42,400
Consultant [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)																1,919
Stock Issued During Period, Value, Issued for Services | $																$ 99,010
Former Board Member [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 11.92									$ 11.92
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)															500
Company Executives [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares																$ 0.6
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)																2,925
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						288.8									$ 288.8
Warrants or Rights, Fair Value Per Share (in dollars per share) | $ / shares						185									$ 185
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)															48 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares						140									$ 140
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares															98.84
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares															60.4	$ 140
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares															142	146.4
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						26									26
Warrants or Rights, Fair Value Per Share (in dollars per share) | $ / shares						13.85									$ 13.85
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)															12 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares						18									$ 18
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares															12.62
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares															18	50.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares															$ 50.8	$ 80
Weighted Average [Member] | Time-Based Stock Option Awards, RSUs, and Warrants [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)															1 year 1 month 13 days
Warrants Issued with Registered Direct Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								185,644	95,239
Warrants and Rights Outstanding, Term (Year)								5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 35.4	$ 44
Class of Warrant or Right, Issued in Period (in shares)								185,644	95,239
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								11,140
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 50.5
Class of Warrant or Right, Issued in Period (in shares)								11,140
Class of Warrant or Right, Cancelled During Period (in shares)															960
Warrants Issued for Services [Member]
Class of Warrant or Right, Issued in Period (in shares)															4,250
Class of Warrant or Right, Cancelled During Period (in shares)															2,568
Warrants Issued for Services [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						66									$ 66
Warrants Issued for Services [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 26									$ 26
Vesting of Warrants For Service Provider [Member]
Share-Based Payment Arrangement, Expense | $															$ 133,558
Warrant For Service Provider [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																1,250
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 55.2
Warrant For Service Provider 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																1,250
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 59.6
Warrant for Services Provided at IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 200
Class of Warrant or Right, Cancelled During Period (in shares)																257
Warrants from Prior Service Providers [Member]
Warrants or Rights, Cancelled During Period (in shares)																3,402
Performance-based Warrant [Member]
Class of Warrant or Right, Outstanding (in shares)						1									1
Warrant, Nonvested Award, Cost Not yet Recognized, Amount | $						$ 300,000									$ 300,000
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)									95,239
Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares									$ 42
Proceeds from Issuance or Sale of Equity | $									$ 3,600,000
Payments of Stock Issuance Costs | $									$ 400,000
July 2023 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)								185,644
Proceeds from Issuance or Sale of Equity | $								$ 6,700,000
Payments of Stock Issuance Costs | $								$ 800,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares								$ 40.4
The 2022 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)															1,342
Brokerage Commissions, Percentage of Gross Proceeds											3%
Proceeds from Issuance of Common Stock | $															$ 78,355
The 2022 ATM Facility [Member] | Maximum [Member]
Common Stock, Shares Authorized, Value | $											$ 50,000,000
The 2023 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)															0
Proceeds from Issuance or Sale of Equity | $															$ 881,946
Brokerage Commissions, Percentage of Gross Proceeds							3%
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)					74,294
Subsequent Event [Member] | Scientific Advisory Board Chairman [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)				125
Subsequent Event [Member] | Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	165,000
Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares	$ 4.215
Proceeds from Issuance or Sale of Equity | $	$ 5.8												$ 5.8
Subsequent Event [Member] | The 2023 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)														158,474
Proceeds from Issuance of Common Stock | $														$ 881,946
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		40	40

Note 4 - Equity - Common Stock

Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding, number of warrants (in shares)	53,695	55,121
Outstanding, weighted average exercise price (in dollars per share)	$ 172.81	$ 175.65
Warrants issued, number of warrants (in shares)	296,273	2,575
Warrants issued, weighted average exercise price (in dollars per share)	$ 38.75	$ 61.55
Exercised, number of warrants (in shares)		342
Exercised, weighted average exercise price (in dollars per share)		$ 20
Warrants cancelled or expired, number of warrants (in shares)	3,528	3,659
Warrants cancelled or expired, weighted average exercise price (in dollars per share)	$ 209.77	$ 151.66
Outstanding, number of warrants (in shares)	346,440	53,695
Outstanding, weighted average exercise price (in dollars per share)	$ 57.79	$ 172.81
Exercisable, number of warrants (in shares)	340,585	47,548
Exercisable, weighted average exercise price (in dollars per share)	$ 57.36	$ 183.42

Note 4 - Equity - Assumptions (

Note 4 - Equity - Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Volatility:	83.42%
Dividend yield:	0%
Share-Based Payment Arrangement, Option [Member]
Expected term (in years): (Year)	6 years	10 years
Dividend yield:	0%	0%
Minimum [Member]
Expected term (in years): (Year)	2 years 6 months
Risk-free rate:	5.33%
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]
Risk-free rate:	4.60%	0.07%
Volatility:	83.14%	75.98%
Maximum [Member]
Expected term (in years): (Year)	3 years
Risk-free rate:	5.52%
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]
Risk-free rate:	5.37%	4.77%
Volatility:	83.42%	88.38%

Note 4 - Equity - Stock Option

Note 4 - Equity - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding, number of shares (in shares)	284,377	214,370
Outstanding, weighted average exercise price (in dollars per share)	$ 123.19	$ 134.14
Options granted, number of shares (in shares)	8,251	74,600
Options granted, weighted average exercise price (in dollars per share)	$ 30.14	$ 86.45
Options exercised, number of shares (in shares)	500	2,925
Options exercised, weighted average exercise price (in dollars per share)	$ 11.92	$ 0.6
Options expired or cancelled, number of shares (in shares)	6,245	1,668
Options expired or cancelled, weighted average exercise price (in dollars per share)	$ 104.42	$ 101.88
Outstanding, number of shares (in shares)	285,883	284,377
Outstanding, weighted average exercise price (in dollars per share)	$ 121.11	$ 123.19
Exercisable, number of shares (in shares)	237,859	167,957
Exercisable, weighted average exercise price (in dollars per share)	$ 124.73	$ 129.19

Note 4 - Equity - Restricted St

Note 4 - Equity - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Outstanding, shares (in shares) | shares
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares
Restricted stock units granted, shares (in shares) | shares	57,119
Restricted stock units granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 60.08
Restricted stock units forfeited or cancelled (in shares) | shares	5,257
Restricted stock units forfeited or cancelled (in dollars per share) | $ / shares	$ 66
Outstanding, shares (in shares) | shares	51,862
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 59.48

Note 5 - 401(k) Savings Trans_2

Note 5 - 401(k) Savings Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Defined Contribution Plan, Cost	$ 141,564	$ 74,281

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Sep. 30, 2022

Jul. 31, 2018

Mar. 31, 2017

Dec. 31, 2023

Dec. 31, 2009

Jul. 14, 2023

Mar. 31, 2023

Dec. 31, 2022

Dec. 29, 2022

Nov. 22, 2022

Mar. 03, 2021

Feb. 11, 2020

License Agreement Terms [Member]

Contract Payments Incurred and Paid

$ 320,000

License Agreement Milestone Payment

$ 6,150,000

National Institute of Health [Member]

Royalty on Sales, Percentage

1%

Royalty Term (Year)

21 years

Royalty Payment, Annual Minimum

$ 20,000

Payment for Contingent Consideration Liability, Operating Activities

$ 240,000

Contingent Payments Annual Increase

$ 20,000

Other Commitment

360,000

$ 340,000

Research Agreement [Member] | MD Anderson [Member]

Long Term Contract, Estimated Cost

$ 2,900,000

$ 2,000,000

Contract Payments Incurred and Paid

1.2

License Agreement [Member] | University of Pittsburgh [Member]

Licensing Fee, Amount

$ 25,000

Annual Maintenance Fee, First Three Years, Amount

25,000

Annual Maintenance Fee, After Year Three, Amount

40,000

Annual Royalty Payment Per Year, Minimum

$ 250,000

Share of Non-Royalty Sublicense Income, Percent

20%

License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member]

Contract Payments Incurred and Paid

110,000

Milestone Payment

$ 3,975,000

License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]

Contract Payments Incurred and Paid

50,000

Licensing Fee, Amount

25,000

$ 25,000

Annual Maintenance Fee, First Three Years, Amount

25,000

Annual Maintenance Fee, After Year Three, Amount

40,000

Annual Royalty Payment Per Year, Minimum

$ 250,000

Share of Non-Royalty Sublicense Income, Percent

20%

Milestone Payment

$ 3,975,000

License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]

Contract Payments Incurred and Paid

25,000

Licensing Fee, Amount

25,000

Annual Maintenance Fee, First Three Years, Amount

$ 25,000

Annual Maintenance Fee, After Year Three, Amount

40,000

Annual Royalty Payment Per Year, Minimum

$ 250,000

Share of Non-Royalty Sublicense Income, Percent

20%

Milestone Payment

$ 3,975,000

License Agreement [Member] | University of Pittsburgh [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]

Contract Payments Incurred and Paid

25,000

Annual Royalty Payment Per Year, Minimum

$ 250,000

Share of Non-Royalty Sublicense Income, Percent

20%

Milestone Payment

$ 4,225,000

Annual Maintenance Fee, First Year, Amount

25,000

Annual Maintenance Fee, Second and Third Year, Amount

50,000

Annual Maintenance Fee, Fourth Year, Amount

$ 100,000

License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member]

Royalty Percent, Licensed Technology Covered by Patent

1.50%

License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]

Royalty Percent, Licensed Technology Covered by Patent

1.50%

License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]

Royalty Percent, Licensed Technology Covered by Patent

1.50%

License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]

Royalty Percent, Licensed Technology Covered by Patent

1.50%

License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member]

Royalty Percent, Licensed Technology Covered by Patent

3%

License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]

Royalty Percent, Licensed Technology Covered by Patent

3%

License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]

Royalty Percent, Licensed Technology Covered by Patent

3%

License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]

Royalty Percent, Licensed Technology Covered by Patent

3%

Development and Manufacturing of GMP Grade Materials [Member]

Contract Payments Incurred and Paid

$ 2,600,000

Development Services Agreement, Expected Total Project Cost

$ 4,500,000

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets, Valuation Allowance	$ 23,420,752	$ 17,119,710
Research Tax Credit Carryforward [Member] | Expiration, 2037 [Member]
Tax Credit Carryforward, Amount	1,400,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 80,500,000	$ 68,900,000

Note 8 - Income Taxes - Provisi

Note 8 - Income Taxes - Provision for Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current Tax Expense (Benefit):
Federal, Current	$ 0	$ 0
State, Current	0	0
Total, Current	0	0
Deferred Tax Expense (Benefit):
Federal, Deferred	0	0
State, Deferred	0	0
Total, Deferred	0	0
Total Provision for Income Taxes	$ 0	$ 0

Note 8 - Income Taxes - Schedul

Note 8 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Allowance for Doubtful Accounts	$ 0	$ 0
Interest Expense	0	0
Intangible Assets - R&D Expenses	4,710,079	1,986,102
Accrued Expenses	684,699	561,496
Tax Credits	1,434,851	728,701
Stock Compensation Expense	306,906	94,237
Net Operating Losses	16,915,002	14,464,170
Total Deferred Income Tax Assets	24,051,538	17,834,706
Fixed Assets	(1,650)	(4,354)
Intangible Assets	0	0
Prepaid Expenses	(629,136)	(710,643)
Lease - Right of Use	0	0
Unrealized Gain/Loss	0	0
Total Deferred Income Tax Liabilities	(630,786)	(714,997)
Less Valuation Allowance	(23,420,752)	(17,119,710)
Net Deferred Income Tax Asset	$ 0	$ 0

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual)

1 Months Ended

3 Months Ended

12 Months Ended

Mar. 21, 2024 USD ($) $ / shares shares

Mar. 14, 2024 shares

Feb. 02, 2024

Jan. 19, 2024

Jan. 03, 2024 shares

Jan. 02, 2024 shares

Jan. 01, 2024 shares

Dec. 31, 2023 $ / shares shares

Mar. 01, 2023 USD ($) $ / shares shares

Jan. 01, 2023 shares

Jan. 01, 2022 shares

Mar. 31, 2024 USD ($)

Mar. 28, 2024 USD ($) shares

Dec. 31, 2023 USD ($) $ / shares shares

Dec. 31, 2022 USD ($) $ / shares shares

Jul. 21, 2023 $ / shares shares

Dec. 31, 2021 $ / shares

Proceeds from Issuance of Common Stock | $

$ 10,593,377

$ 6,426

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

346,440

346,440

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 57.79

$ 57.79

$ 172.81

$ 175.65

Warrants and Rights Outstanding, Term (Year)

5 years

5 years

Maximum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 288.8

$ 288.8

Warrants Issued with Registered Direct Offering [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

95,239

185,644

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 44

$ 35.4

Warrants and Rights Outstanding, Term (Year)

5 years

5 years

The 2023 ATM Facility [Member]

Stock Issued During Period, Shares, New Issues (in shares)

0

Proceeds from Issuance or Sale of Equity | $

$ 881,946

Registered Direct Offering [Member]

Stock Issued During Period, Shares, New Issues (in shares)

95,239

Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares

$ 42

Proceeds from Issuance or Sale of Equity | $

$ 3,600,000

Scientific Advisory Board Chairman [Member]

Stock Issued During Period, Shares, Issued for Services (in shares)

500

500

Subsequent Event [Member] | March 2024 Pre-Funded Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.0001

Subsequent Event [Member] | March 2024 Pre-Funded Warrants [Member] | Maximum [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

1,377,112

Subsequent Event [Member] | March 2024 Common Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 4.09

Warrants and Rights Outstanding, Term (Year)

5 years

Subsequent Event [Member] | March 2024 Common Warrants [Member] | Maximum [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

1,542,112

Subsequent Event [Member] | March 2024 Pre-Funded Warrant and Common Warrant [Member]

Class of Warrant or Right, Combined Purchase Price | $

$ 4.2149

Subsequent Event [Member] | Amended Registered Direct Offering [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 4.09

Warrants and Rights Outstanding, Term (Year)

5 years

Class of Warrant or Right, Amendment Price Per Warrant (in dollars per share) | $ / shares

$ 0.125

Subsequent Event [Member] | Amended Registered Direct Offering [Member] | Maximum [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

194,248

Subsequent Event [Member] | Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

40

40

Subsequent Event [Member] | The 2023 ATM Facility [Member]

Stock Issued During Period, Shares, New Issues (in shares)

158,474

Proceeds from Issuance of Common Stock | $

$ 881,946

Subsequent Event [Member] | Registered Direct Offering [Member]

Stock Issued During Period, Shares, New Issues (in shares)

165,000

Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares

$ 4.215

Proceeds from Issuance or Sale of Equity | $

$ 5.8

$ 5.8

Subsequent Event [Member] | Scientific Advisory Board Chairman [Member]

Stock Issued During Period, Shares, Issued for Services (in shares)

125

Subsequent Event [Member] | Service Providers [Member]

Stock Issued During Period, Shares, Issued for Services (in shares)

30,000

6,250

The 2018 Equity Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)

74,294

60,132

59,843

The 2018 Equity Incentive Plan [Member] | Subsequent Event [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)

74,294